Mode
Text Size
Log in / Sign up

TVU during cervical screening detects 81.6% of ovarian cancers at stage I in large cohortCan a routine ultrasound during cervical screening catch ovarian cancer early?

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Interpret high stage I detection rates from TVU screening cautiously; study lacks mortality outcomes and control group.

This observational study analyzed data from 483,269 women who underwent transvaginal ultrasound (TVU) concurrently with cervical cancer screening between 2014 and 2022. The intervention was TVU performed at the same time as cervical screening, with no specific comparator group reported. Among the screened population, 3,294 women (0.68%) were selected for detailed examination based on TVU findings. Of the 550 women who subsequently underwent surgery, 80 cases of ovarian cancer were confirmed, yielding a positive predictive value of 2.43% for TVU in this setting. Among 76 cases with available pathologic review, 62 (81.6%) were detected at clinical stage I. The stage I detection rate was significantly higher for type I epithelial ovarian cancers (46 of 54 cases, 87.3%) compared to type II tumors (9 of 16 cases, 56.3%; P = 0.0068). For clear cell carcinoma specifically, 22 of 23 cases (95.7%) were detected at stage I. Safety and tolerability data for the screening procedure were not reported. Key limitations include the observational design without a control group for comparison of outcomes, lack of reported mortality data, and absence of information on adverse events or procedure-related complications. The study's relevance to practice is restrained; while it demonstrates that TVU screening in this context can detect a high proportion of ovarian cancers at an early stage, particularly type I tumors, it does not establish whether this early detection translates to improved survival. The authors suggest these findings may warrant reassessment of TVU screening utility in regions like Asia where type I ovarian cancer is more common, but comparative data from other regions are lacking.

Ovarian cancer is often called a silent killer because it's usually found too late. A new look at a massive screening program in Japan offers a glimmer of hope. When nearly half a million women getting routine cervical cancer checks also received a transvaginal ultrasound, the test flagged about 3,300 women for a closer look. From that group, 80 cases of ovarian cancer were ultimately found.

The striking finding was how early these cancers were caught. Among the confirmed cases, more than 80% were diagnosed at stage I, when the disease is most curable. The success was especially high for specific types of ovarian tumors, like clear cell carcinoma, where 95% were found at stage I.

This data challenges the long-held view that ultrasound screening for ovarian cancer in the general population is ineffective. The authors suggest it might be time to reconsider, particularly in regions like Asia where these more easily detectable tumor types are common. It's important to temper optimism, though. This was an observational study within an existing screening program—there was no comparison group of women who weren't screened. We don't know if finding these cancers earlier actually led to fewer deaths, which is the ultimate goal of any screening test.

What this means for you:
Routine ultrasound found most ovarian cancers early, but it's not yet proven to save lives.

Study Details

EvidenceLevel 5
PublishedApr 2026
View Original Abstract ↓
OBJECTIVE: Early detection of ovarian cancer at stage I is important to improve patients' prognosis. The goal of this study was to examine if transvaginal ultrasound (TVU) performed at the same time as cervical cancer screening can facilitate early detection of ovarian cancer. METHODS: From 2014 to 2022, 483 269 women underwent TVU examinations during cervical cancer screening. The criteria for abnormal findings on TVU were ovarian enlargement ≥3 cm in long diameter (≥2 cm in postmenopausal women). RESULTS: Of the 483 269 women who underwent TVU, 3294 (0.68%) were selected for detailed examination. Of these women, 550 underwent surgery and 80 cases of ovarian cancer were found (positive predictive value: 2.43%). Pathologic review in 76 of these cases showed 70 cases of epithelial ovarian cancer (type I: 54 [77.1%], Type II: 16 [22.9%]) and six cases of non-epithelial malignant tumors. Clinical staging analysis showed that 81.6% (62 cases) were at stage I. Significantly more type I than type II tumors were detected at stage I (87.3% (n = 46) vs. 56.3%, P = 0.0068 (n = 9)). Notably, 95.7% (22/23) of clear cell carcinoma cases were detected at stage I. DISCUSSION: The high rate of early detection of type I ovarian cancer might be due to its slow progression. In Asia, where type I is common, the benefits of screening for ovarian cancer are particularly great. However, screening with TVU has generally been considered to have little benefit. The results of this study suggest a need for reassessment of this view.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.